Antiplatelet agents: rationale and results.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D003094:Collagen / Q000494:pharmacology; D003327:Coronary Disease / Q000209:etiology; D004176:Dipyridamole / Q000494:pharmacology; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000209:etiology; D008297:Male; D009203:Myocardial Infarction / Q000517:prevention & control; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D012737:Sex Factors; D013442:Sulfinpyrazone / Q000494:pharmacology / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology
D000319:Adrenergic beta-Antagonists; D001095:Arachidonic Acids; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D003094:Collagen; D001241:Aspirin; D013442:Sulfinpyrazone